• Disease
  • Type
  • Type 2
  • Type 2 Diabetes
  • Barry M Brenner

    Prominent publications by Barry M Brenner

    KOL Index score: 22022

    BACKGROUND: Proteinuria or albuminuria is an established risk marker for progressive renal function loss. Albuminuria can be effectively lowered with antihypertensive drugs that interrupt the renin-angiotensin system (RAS). We investigated whether albuminuria could not only serve as a marker of renal disease, but also function as a monitor of the renoprotective efficacy of RAS intervention by the angiotensin II (Ang II) antagonist, losartan, in patients with diabetic ...

    Also Ranks for: 2 Diabetic |  renal outcome |  baseline albuminuria |  losartan patients |  6 months
    KOL Index score: 16802

    BACKGROUND: Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes.

    METHODS: In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, ...

    Also Ranks for: Type 2 Diabetes |  renal outcomes |  hazard ratio |  canagliflozin lower risk |  endstage kidney disease
    KOL Index score: 16766

    OBJECTIVE: To evaluate the within-trial effect of losartan and conventional antihypertensive therapy (CT) compared with placebo and CT on the economic cost associated with end-stage renal disease (ESRD).

    RESEARCH DESIGN AND METHODS: The Reduction of End Points in Type 2 Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study was a multinational double-blind randomized placebo-controlled clinical trial designed to evaluate the renal protective effects of losartan on a ...

    Also Ranks for: Cost Esrd |  economic evaluation |  losartan reduction |  type 2 diabetes |  renaal study
    KOL Index score: 16497

    Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Glomerular permselectivity to macromolecules, glomerular morphology, and glomerular localization of tracer macromolecules in four groups of male Munich-Wistar rats were studied. Group 1 rats underwent a laparotomy and sham nephrectomy and were fed a standard diet. Group 2 rats underwent right nephrectomy and infarction of five sixths of the left kidney and were fed a standard diet. Both ...

    Also Ranks for: Renal Mass |  glomerular permselectivity |  progressive sclerosis |  fractional clearances |  2 rats
    KOL Index score: 16361

    BACKGROUND: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention).

    METHODS: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly ...

    Also Ranks for: Chronic Kidney Disease |  type 2 |  renal outcomes |  kidney failure |  canagliflozin risk
    KOL Index score: 16086

    BACKGROUND: Patients with type 2 diabetes are at increased risk of macro- and microvascular disease, and the presence of albuminuria and/or reduced kidney function further enhances macrovascular risk. Angiotensin-converting-enzyme inhibitors reduce both macro- and microvascular events, yet the residual renal and cardiovascular risk still remains high. Aliskiren a novel oral direct renin inhibitor that unlike ACEi and ARBs, lowers plasma renin activity, angiotensin I and angiotensin II ...

    Also Ranks for: Type 2 Diabetes |  aliskiren trial |  acei arb |  renal endpoints |  composite endpoint
    KOL Index score: 14926

    The cytokine interleukin 1 (IL-1) inhibits contractile responses in rat aorta by causing endothelium-independent and prolonged activation of soluble guanylate cyclase. The present study tested whether IL-1 activates guanylate cyclase by inducing prolonged production of nitric oxide in cultured rat aortic vascular smooth muscle cells (VSMC). IL-1 induced a marked time-dependent increase in cyclic guanosine monophosphate (cGMP) in VSMC which was significant at 6 h, and increased ...

    Also Ranks for: Nitrite Production |  vsmc il1 |  rat vascular |  guanylate cyclase |  muscle cells
    KOL Index score: 14555

    Micropuncture and morphologic studies were performed in six groups of male Munich-Wistar rats after removal of the right kidney and segmental infarction of two-thirds of the left kidney. Groups 1 and 4 received no specific therapy. Groups 2 and 5 were treated with the angiotensin I-converting enzyme inhibitor, enalapril, 50 mg/liter, in the drinking water. Groups 3 and 6 were treated with reserpine (5 mg/liter), hydralazine (80 mg/liter), and hydrochlorothiazide (25 mg/liter). All rats ...

    Also Ranks for: Systemic Hypertension |  enzyme inhibitor |  rats glomerular |  progressive proteinuria |  therapeutic advantage
    KOL Index score: 14201

    Type 2 diabetes is the leading cause of end-stage renal disease (ESRD) in most industrialized countries in Europe. The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) Study evaluated the renal protective effects of losartan versus placebo on a background of non-ACE-I/non-AIIA conventional antihypertensive therapy in 1513 patients with type 2 diabetes and nephropathy. Losartan reduced the incidence of doubling of serum creatinine, end-stage renal ...

    Also Ranks for: Renaal Study |  esrd patients |  35 years |  type 2 diabetes |  endstage renal disease
    KOL Index score: 13815

    BACKGROUND: Albuminuria is an established risk marker for both cardiovascular and renal outcomes. Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention.

    METHODS AND RESULTS: We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), ...

    Also Ranks for: Cardiovascular Protection |  therapeutic target |  albuminuria patients |  type 2 |  heart failure
    KOL Index score: 13410

    In landmark clinical trials, pharmacological inhibition of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors (ACEIs) attenuated the decline in renal function associated with chronic renal disease (CRD). Hemodynamic and nonhemodynamic effects of angiotensin II (Ang II) attest to its central role in the pathogenesis of CRD. Angiotensin II subtype 1 receptor antagonists (AT1RA) differ from ACEI in their effects on the RAS and on bradykinin metabolism. ...

    Also Ranks for: Ras Inhibition |  acei angiotensin |  2 receptors |  renal function |  type 1
    KOL Index score: 13302

    Adrenomedullin (AM) has vasodilator and diuretic actions, similarly to natriuretic peptides. AM receptor complexes are composed of calcitonin receptor-like receptor (CRLR) and receptor-activity modifying protein-2 (RAMP2), or CRLR and RAMP3. We aimed to know whether gene expression of AM and AM receptor complexes are regulated in kidneys under pathophysiological conditions. Expression of AM, RAMP2, RAMP3 and CRLR mRNA was studied in the remnant kidney of rats with renal mass ablation ...

    Also Ranks for: Activity Modifying |  calcitonin receptor |  remnant kidneys |  ramp2 ramp3 |  gene expression
    KOL Index score: 13107

    BACKGROUND: Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin-angiotensin system slows the progression of renal disease in patients with type 1 diabetes, but similar data are not available for patients with type 2, the most common form of diabetes. We assessed the role of the angiotensin-II-receptor antagonist losartan in patients with type 2 diabetes and nephropathy.

    METHODS: A total of 1513 patients were enrolled in this randomized, ...

    Also Ranks for: Patients Losartan |  2 diabetes |  cardiovascular outcomes |  rate progression |  renal disease
    KOL Index score: 12929

    Cultured endothelial cells release a potent vasoconstrictor peptide, endothelin. Cumulative addition of synthetic endothelin to isolated rabbit aortic rings elicited a concentration-dependent increase in contractile tension which was endothelium-independent. In cultured rabbit vascular smooth muscle cells loaded with the fluorescent dye fura 2, endothelin induced a concentration-dependent increase in [Ca2+]i over the range of 0.01 to 100 nM. Moreover, in the absence of extracellular ...

    Also Ranks for: Vascular Smooth |  endothelin action |  inositol trisphosphate |  calcium mobilization |  cell surface receptors


    Barry M Brenner: Influence Statistics

    Sample of concepts for which Barry M Brenner is among the top experts in the world.
    Concept World rank
    maturational development #1
    pdextran pinulin dextrans #1
    measurable restriction #1
    kf parathyroid hormone #1
    losartan risk reduction #1
    losartan reduction #1
    uprv csn #1
    sngfr lesser extent #1
    renaal life #1
    cap pgc #1
    nif fos #1
    peritubular starling forces #1
    isoncotic #1
    reversing glomerular #1
    peritubular starling #1
    glomerular transcapillary #1
    cardiorenal points #1
    reduction esrd #1
    intrarenal hypertension #1
    glomerulotubular balance rat #1
    59029a allele risk #1
    hypertension renal factor #1
    endothelin vascular ibuprofen #1
    stabilizes established #1
    deltap nontptx rats #1
    opportunity risk predictors #1
    kidney dysfunction life #1
    saralasin sq20881 #1
    losartan renal outcomes #1
    proteinuric individuals #1
    pth aii #1
    glomerular hypertension development #1
    gfr panperfused kidneys #1
    pge2 glomerular microcirculation #1
    delta qa #1
    laterlife hypertension #1
    capillary colloid #1
    f344 lew proteinuria #1
    normal hydropenia #1
    peptides direct action #1
    physiologic regulation #1
    sbp oma #1
    development adult disease #1
    nanoliter blood samples #1
    effectors kidney #1
    carotid arteries constriction #1
    maximal renal protection #1
    individual capillary segments #1
    gentamicin 6 rats #1
    at1ra acei #1

    Key People For Type 2 Diabetes

    Top KOLs in the world
    David Richard Matthews
    type 2 diabetes sri lanka growth hormone
    Frank B Hu
    type 2 diabetes cardiovascular disease physical activity
    Rury R Holman
    type 2 diabetes cardiovascular disease impaired glucose tolerance
    David Matthew Nathan
    type 2 diabetes insulin resistance cardiovascular disease
    John B Buse
    type 2 diabetes insulin degludec cardiovascular outcomes
    Tuomilehto Tuomilehto
    type 2 diabetes blood pressure north karelia

    Barry M Brenner:Expert Impact

    Concepts for whichBarry M Brennerhas direct influence:Type 2 diabetes,  Renaal study,  Renal disease,  Glomerular injury,  Kidney disease,  Glomerular filtration,  Filtration rate,  Glomerular ultrafiltration.

    Barry M Brenner:KOL impact

    Concepts related to the work of other authors for whichfor which Barry M Brenner has influence:Diabetic nephropathy,  Blood pressure,  Chronic kidney disease,  Renal function,  Heart failure,  Type 2 diabetes,  Nitric oxide.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Renal Division and Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (B.M.B.). | From the George Institute for Global Health, University of New South Wales Sydney (V.P., M.J.J., B.N., S. Bompoint), the Royal Nor